A Phase 2 interventional study of Bupivacaine HCl and SKY0402 in Postoperative Pain, sponsored by Pacira Pharmaceuticals, Inc. Completed at 7 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-02.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.
Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 114th largest by enrollment, is one of 7 that started in 2007, is one of 43 in phase 2, and was the 5th registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.
Browse Pain, Postoperative studies →57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Hitit University · Sites in Turkey
Ages 18–75
Wah Medical college , POF hospital · Sites in Pakistan
Ages 18–60
Tianjin First Central Hospital · Sites in China
Ages 18–80
Erkan Gol · Sites in Turkey
Ages 18+ · Women only
By country, each count listing its studies:
Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
364 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 57 · Phase 3 53 · Phase 4 133
First in 2004; this study’s year is marked. 7 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 98 is above the median of 75 across 4,835 interventional studies indexed under Pain, Postoperative.
Median enrollment 70 across the 364 interventional studies. Of the 258 that completed or were terminated, 106 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 364 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pacira Pharmaceuticals, Inc, one of the names counted as Pacira BioSciences, Inc.. Under that name alone:
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.
25 studies in Pain, Postoperative by Pacira BioSciences, Inc.: 1 open now, 1 under way, none of them phase 3. Of 24 finished, 19 (79%) have results posted.
Among the 25 studies in Pain, Postoperative by Pacira BioSciences, Inc., this one is the 9th largest by enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2007, is one of 7 in phase 2, and was the 1st registered.
Pacira BioSciences, Inc.’s Pain, Postoperative studies by the year they started, since 2004.
22 of the studies testing bupivacaine in Pain, Postoperative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06350981Phase 3Foundation for Orthopaedic Research and EducationAnalgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion | 2027-01-01 |
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT07650760Wah Medical college , POF hospitalComparison of Intraperitoneal Bupivacaine and Saline Irrigation for Pain Relief After Laparoscopic Cholecystectomy | 2026-12 |
| NCT03737292Milton S. Hershey Medical CenterLiposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy | 2026-12 |
| NCT02381353Mayo ClinicExparel Injection for Postoperative Orbital Pain | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 364 studies testing bupivacaine in Pain, Postoperative, from their registry updates:
Among Pacira BioSciences, Inc.’s 25 in Pain, Postoperative:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate three dose levels of SKY0402 compared with 105 mg of bupivacaine HCl.
Effective postoperative pain control is a critical element in patient recovery, as the majority of patients may experience significant pain, particularly in the first few days following surgery. Appropriate postoperative pain management contributes to improved healing, faster patient mobilization, shortened hospital stays, and reduced healthcare costs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Use of any of the following medications within the times specified before surgery:
Current or historical evidence of any condition that, in the opinion of the Investigator, may increase the risk of surgery, complicate the subject's postoperative course, or indicate an increased vulnerability to study drugs and procedures and expose the subject to an unreasonable risk as a result of participating in this clinical trial.
If during surgery the following criterion is met:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bupivacaine HCl given during hernia repair
Drug: Bupivacaine HCl
SKY0402 low dose given during hernia repair
Drug: SKY0402
SKY0402 middle dose given during hernia repair
Drug: SKY0402
SKY0402 high dose given during hernia repair
Drug: SKY0402
Bupivacaine HCl given during hernia repair
Also known as: Marcaine 0.25% with epinephrine 1:200,000
SKY0402 given during hernia repair
Also known as: EXPAREL
Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores From 0 Through 72 Hours
The subject's pain intensity was to be assessed with activity (NRS-A), after the subject had moved himself from a supine position in bed to a sitting up position at the edge of the bed. The subject was to respond to the following question: "On a scale of 0 to 10, where 0=no pain and 10=worst possible pain, how much pain did you have while sitting up?"
Time frame: 0 to 72 hours
Number of Participants With Adverse Events Through 96 Hours or Serious Adverse Events Through 30 Days
Time frame: Up to 30 days
| Milestone | Bupivacaine HCl 105mg | SKY0402 Low Dose | SKY0402 Middle Dose | SKY0402 High Dose |
|---|---|---|---|---|
| Started | 24 | 25 | 24 | 25 |
| Completed | 24 | 25 | 24 | 25 |
| Not completed | 0 | 0 | 0 | 0 |
The subject's pain intensity was to be assessed with activity (NRS-A), after the subject had moved himself from a supine position in bed to a sitting up position at the edge of the bed. The subject was to respond to the following question: "On a scale of 0 to 10, where 0=no pain and 10=worst possible pain, how much pain did you have while sitting up?"
| Units on a scale*hours | Bupivacaine HCl 105mg | SKY0402 Low Dose | SKY0402 Middle Dose | SKY0402 High Dose |
|---|---|---|---|---|
| Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores From 0 Through 72 Hours | 298.1 ± 136.6 | 286.9 ± 146.4 | 274.6 ± 115.4 | 274.4 ± 253.4 |
Results for this outcome have not been posted.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bupivacaine HCl 105mg | — | 0/24 (0%) | 10/24 (41.7%) |
| SKY0402 (All Doses) | — | 1/74 (1.4%) | 17/74 (23%) |
| Event | Bupivacaine HCl 105mg | SKY0402 (All Doses) |
|---|---|---|
| ScarInjury, poisoning and procedural complications | 0/24 | 1/74 |
| Event | Bupivacaine HCl 105mg | SKY0402 (All Doses) |
|---|---|---|
| NauseaGastrointestinal disorders | 5/24 | 6/74 |
| ConstipationGastrointestinal disorders | 2/24 | 7/74 |
| DizzinessNervous system disorders | 2/24 | 6/74 |
| HypoaesthesiaNervous system disorders | 2/24 | 1/74 |
| BradycardiaCardiac disorders | 0/24 | 4/74 |
| Age, Categorical(Participants) | Bupivacaine HCl 105mg | SKY0402 Low Dose | SKY0402 Middle Dose | SKY0402 High Dose | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 21 | 19 | 18 | 21 | 79 |
| >=65 years | 3 | 6 | 6 | 4 | 19 |
| Age, Continuous(years) | Bupivacaine HCl 105mg | SKY0402 Low Dose | SKY0402 Middle Dose | SKY0402 High Dose | Total |
|---|---|---|---|---|---|
| Mean | 47.3 ± 16.9 | 51.2 ± 17.3 | 54 ± 15.1 | 52.1 ± 15.6 | 51.1 ± 16.2 |
| Sex: Female, Male(Participants) | Bupivacaine HCl 105mg | SKY0402 Low Dose | SKY0402 Middle Dose | SKY0402 High Dose | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 24 | 25 | 24 | 25 | 98 |
| Region of Enrollment(participants) | Bupivacaine HCl 105mg | SKY0402 Low Dose | SKY0402 Middle Dose | SKY0402 High Dose | Total |
|---|---|---|---|---|---|
| United States | 24 | 25 | 24 | 25 | 98 |
The record gives a start of Jun 2007, a primary completion of Dec 2007 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 5 years 8 months after primary completion. A results delay was requested in Aug 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupivacaine